IE
BBIO icon

Israel Englander’s BridgeBio Pharma BBIO Stock Holding History

Israel Englander’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.3M Sell
487,594
-145,689
-23% -$10.2M 0.01% 1119
2026
Q1 		$47M Buy
633,283
+596,698
+1,631% +$43.3M 0.02% 863
2025
Q4 		$2.8M Sell
36,585
-133,852
-79% -$8.79M ﹤0.01% 3633
2025
Q3 		$8.85M Sell
170,437
-450,021
-73% -$21.9M ﹤0.01% 2514
2025
Q2 		$26.8M Buy
620,458
+380,538
+159% +$13.8M 0.01% 1307
2025
Q1 		$8.29M Buy
239,920
+128,849
+116% +$4.34M ﹤0.01% 2376
2024
Q4 		$3.05M Buy
111,071
+73,599
+196% +$1.9M ﹤0.01% 3291
2024
Q3 		$954K Sell
37,472
-204,308
-85% -$5.36M ﹤0.01% 4318
2024
Q2 		$6.12M Buy
241,780
+125,178
+107% +$3.42M ﹤0.01% 2530
2024
Q1 		$3.61M Buy
116,602
+60,839
+109% +$2.07M ﹤0.01% 3208
2023
Q4 		$2.25M Sell
55,763
-410,291
-88% -$12.3M ﹤0.01% 3506
2023
Q3 		$12.3M Buy
+466,054
New +$13.2M 0.01% 1859
2023
Q2 		– Sell
-310,569
Closed -$4.67M – 6110
2023
Q1 		$5.15M Buy
310,569
+226,392
+269% +$2.64M ﹤0.01% 2581
2022
Q4 		$641K Sell
84,177
-1,081,131
-93% -$10.4M ﹤0.01% 4548
2022
Q3 		$11.6M Buy
1,165,308
+563,441
+94% +$5.85M 0.01% 1958
2022
Q2 		$5.46M Sell
601,867
-315,942
-34% -$2.64M ﹤0.01% 2705
2022
Q1 		$9.32M Sell
917,809
-578,264
-39% -$5.93M ﹤0.01% 2239
2021
Q4 		$25M Buy
1,496,073
+1,258,858
+531% +$53.3M 0.01% 1246
2021
Q3 		$11.1M Buy
237,215
+96,204
+68% +$5.16M 0.01% 1918
2021
Q2 		$8.6M Buy
141,011
+99,169
+237% +$5.66M 0.01% 2101
2021
Q1 		$2.58M Sell
41,842
-51,600
-55% -$3.38M ﹤0.01% 3281
2020
Q4 		$6.64M Buy
+93,442
New +$4.51M ﹤0.01% 2170
2020
Q3 		– Sell
-39,680
Closed -$1.29M – 4439
2020
Q2 		$1.29M Sell
39,680
-196,520
-83% -$5.99M ﹤0.01% 2834
2020
Q1 		$6.85M Buy
+236,200
New +$7.32M 0.02% 1108
2019
Q4 		– Sell
-37,382
Closed -$802K – 4199
2019
Q3 		$802K Sell
37,382
-342,537
-90% -$9.48M ﹤0.01% 2975
2019
Q2 		$10.2M Buy
+379,919
New +$10.4M 0.02% 1231

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Israel Englander's BBIO Position: Q2 2026 in Review

Israel Englander reduced its BridgeBio Pharma (BBIO) stake by 23% in Q2 2026, selling an estimated $10.2M and leaving 487,594 shares worth $36.3M. The position accounts for 0.01% of the portfolio, ranked #1119.

Israel Englander first reported a position in BBIO in Q2 2019 and has held it in 26 quarters since. The position peaked at $47M in Q1 2026. 472 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Israel Englander held 487,594 shares of BridgeBio Pharma worth $36.3M as of Q2 2026.
  • Israel Englander sold 145,689 BridgeBio Pharma shares in Q2 2026, an estimated $10.2M.
  • BridgeBio Pharma made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1119 holding.
  • Israel Englander first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 26 quarters since.
  • Israel Englander's BridgeBio Pharma position peaked at $47M in Q1 2026.
  • 472 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.